CU24750B1 - Entidades peptídicas con actividad antimicrobiana frente a patógenos multi-drogoresistentes - Google Patents

Entidades peptídicas con actividad antimicrobiana frente a patógenos multi-drogoresistentes

Info

Publication number
CU24750B1
CU24750B1 CU2020000086A CU20200086A CU24750B1 CU 24750 B1 CU24750 B1 CU 24750B1 CU 2020000086 A CU2020000086 A CU 2020000086A CU 20200086 A CU20200086 A CU 20200086A CU 24750 B1 CU24750 B1 CU 24750B1
Authority
CU
Cuba
Prior art keywords
entities
drug
activity against
antimicrobial activity
resistant pathogens
Prior art date
Application number
CU2020000086A
Other languages
English (en)
Other versions
CU20200086A7 (es
Inventor
Perez Hilda Elisa Garay
Vivian Montero-Alejo
Rolando Perdomo-Morales
González Amanda Vázquez
Original Assignee
Centro De Investig Y Desarrollo De Medicamentos Cidem
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centro De Investig Y Desarrollo De Medicamentos Cidem filed Critical Centro De Investig Y Desarrollo De Medicamentos Cidem
Priority to CU2020000086A priority Critical patent/CU24750B1/es
Priority to MX2023005925A priority patent/MX2023005925A/es
Priority to PCT/CU2021/050011 priority patent/WO2022105948A2/es
Priority to US18/037,534 priority patent/US20240239849A1/en
Priority to JP2023523524A priority patent/JP2024508205A/ja
Priority to CN202180071094.XA priority patent/CN116406282A/zh
Priority to CA3199519A priority patent/CA3199519A1/en
Priority to EP21865361.6A priority patent/EP4249500A2/en
Publication of CU20200086A7 publication Critical patent/CU20200086A7/es
Priority to CONC2023/0007878A priority patent/CO2023007878A2/es
Publication of CU24750B1 publication Critical patent/CU24750B1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43509—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from crustaceans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Insects & Arthropods (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

<p>La presente invención describe nuevas entidades peptídicas sintéticas que combaten microorganismos patógenos de naturaleza bacteriana, y que se presentan como microorganismos multirresistentes a antibióticos convencionales. Estas entidades muestran además, que el diseño racional basado en estructura, permite obtener en una misma estructura varias actividades favorables en un ambiente infeccioso como son, la actividad anti-LPS y la actividad moduladora de citocinas inflamatorias inducidas por lipopolisacáridos en un cultivo de sangre total.</p>
CU2020000086A 2020-11-19 2020-11-19 Entidades peptídicas con actividad antimicrobiana frente a patógenos multi-drogoresistentes CU24750B1 (es)

Priority Applications (9)

Application Number Priority Date Filing Date Title
CU2020000086A CU24750B1 (es) 2020-11-19 2020-11-19 Entidades peptídicas con actividad antimicrobiana frente a patógenos multi-drogoresistentes
MX2023005925A MX2023005925A (es) 2020-11-19 2021-11-18 Entidades peptidicas con actividad antimicrobiana frente a patogenos multi-drogoresistentes.
PCT/CU2021/050011 WO2022105948A2 (es) 2020-11-19 2021-11-18 Entidades peptídicas con actividad antimicrobiana frente a patógenos multi-drogoresistentes
US18/037,534 US20240239849A1 (en) 2020-11-19 2021-11-18 Peptide entities with antimicrobial activity against multi-drug resistant pathogens
JP2023523524A JP2024508205A (ja) 2020-11-19 2021-11-18 多剤耐性病原体に対する抗菌活性を有するペプチド実体
CN202180071094.XA CN116406282A (zh) 2020-11-19 2021-11-18 具有针对多药耐药性病原体的抗微生物活性的肽实体
CA3199519A CA3199519A1 (en) 2020-11-19 2021-11-18 Peptide entities with antimicrobial activity against multi-drug resistant pathogens
EP21865361.6A EP4249500A2 (en) 2020-11-19 2021-11-18 Peptide entities with antimicrobial activity against multi-drug resistant pathogens
CONC2023/0007878A CO2023007878A2 (es) 2020-11-19 2023-06-15 Entidades peptídicas con actividad antimicrobiana frente a patógenos multi-drogoresistentes

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU2020000086A CU24750B1 (es) 2020-11-19 2020-11-19 Entidades peptídicas con actividad antimicrobiana frente a patógenos multi-drogoresistentes

Publications (2)

Publication Number Publication Date
CU20200086A7 CU20200086A7 (es) 2022-06-06
CU24750B1 true CU24750B1 (es) 2025-06-11

Family

ID=80684162

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2020000086A CU24750B1 (es) 2020-11-19 2020-11-19 Entidades peptídicas con actividad antimicrobiana frente a patógenos multi-drogoresistentes

Country Status (9)

Country Link
US (1) US20240239849A1 (es)
EP (1) EP4249500A2 (es)
JP (1) JP2024508205A (es)
CN (1) CN116406282A (es)
CA (1) CA3199519A1 (es)
CO (1) CO2023007878A2 (es)
CU (1) CU24750B1 (es)
MX (1) MX2023005925A (es)
WO (1) WO2022105948A2 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117756904B (zh) * 2023-12-22 2024-05-24 潍坊医学院 一种订书肽及其应用
CN118666967B (zh) * 2024-03-06 2025-03-28 广东医保药业有限公司 多肽及其与头孢噻肟舒巴坦的组合

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69637731D1 (de) * 1995-08-23 2008-12-11 Univ British Columbia Antimikrobielle kationische peptide und methoden zu ihrer identifizierung
CU24073B1 (es) 2011-12-27 2015-01-29 Ct De Investigación Y Desarrollo De Medicamentos Cidem COMPOSICIÓN A PARTIR DE EXTRACTO DE HEMOCITOS DE LANGOSTA PARA LA DETECCIÓN DE LIPOPOLISACÁRIDOS, PEPTIDOGLICANOS Y 1,3-ß-D-GLUCANOS
CA3062852A1 (en) * 2017-05-11 2018-11-15 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Antimicrobial peptides with alpha-core helices
EP3946609A4 (en) * 2019-04-05 2023-05-03 Contrafect Corporation LYSINE AND ITS DERIVATIVES WITH BACTERICIDAL ACTIVITY AGAINST PSEUDOMONAS AERUGINOSA IN THE PRESENCE OF HUMAN SERUM

Also Published As

Publication number Publication date
CA3199519A1 (en) 2022-05-27
CN116406282A (zh) 2023-07-07
WO2022105948A3 (es) 2022-10-20
MX2023005925A (es) 2023-05-29
WO2022105948A2 (es) 2022-05-27
US20240239849A1 (en) 2024-07-18
EP4249500A2 (en) 2023-09-27
CU20200086A7 (es) 2022-06-06
CO2023007878A2 (es) 2023-07-21
JP2024508205A (ja) 2024-02-26

Similar Documents

Publication Publication Date Title
CU24750B1 (es) Entidades peptídicas con actividad antimicrobiana frente a patógenos multi-drogoresistentes
BR112014031658A2 (pt) método mixotrófico de aquicultura
NI201200014A (es) Anticuerpos humanos de alta afinidad para la angiopoyetina - 2 humana
ECSP15022090A (es) Composición que comprende agentes de control biológico
AR119025A1 (es) Composición que comprende un bacillus formador de biopelícula
ES2530858T3 (es) Comida para mascotas, recubierta a vacío
CL2019002135A1 (es) Células microbianas, métodos para producir las mismas, y usos de las mismas.
PE20121693A1 (es) Combinacion de espiromesifeno y abamectina como insecticidas
CO2022005107A2 (es) Bacterias productoras de serotonina
BR112014014662A8 (pt) uso de derivados de diamina antranílica com substituintes heteroaromáticos e heterocíclicos em combinação com um agente de controle biológico
CL2020001816A1 (es) Bacterias probióticas para peces.
MX2022003839A (es) Uso de microorganismo para mejorar la productividad vegetal del suelo.
BR112012024999A2 (pt) combinação e uso
MX2022001428A (es) Metodos y composiciones para cultivar bacterias dependientes de hemoglobina.
PY2213223A (es) Bacterias que confieren propiedades bioprotectoras y/o biofertilizantes
CL2023000979A1 (es) Cepas de pseudomonas y sus metabolitos para controlar enfermedades de los peces
TWD215530S (zh) 圍兜
AR113143A1 (es) Cepa de tolypocladium album y su uso como plaguicida biológico
MX2020001043A (es) Tolanos sustituidos para la modulacion de la colonizacion microbiana.
BR112023022923A2 (pt) Composto antibacteriano
Shukuru et al. Bioagents and beyond: harnessing the diversity of nematophagous microorganisms and predators for sustainable management of plant–parasitic nematodes
EA201991891A1 (ru) Антибиотические соединения арилоксазолидинона
Amin Evaluation of rhizobacteria effects on the activity of root-knot nematode, Meloidogyne incognita, under greenhouse and laboratory conditions.
Nazarov et al. A novel kinase provides self-resistance to isocoumarin antibiotic amicoumacin A in Bacillus
ODABAŞ et al. METISILIN DIRENÇLI STAPHYLOCOCCUS AUREUS SUşLARıNA KARşı KARVAKROL VE OKSASILININ KOMBINASYON AKTIVITESININ İN VITRO DEğERLENDIRILMESI